美國米利亞德基因Myriad Genetics www.myriad.com
Myriad Genetics成立于1991年,使用以基因醫(yī)學(xué)來開發(fā)醫(yī)療及分子診斷產(chǎn)品。他們利用多種專有proteomic技術(shù)來發(fā)現(xiàn)疾病基因并了解這些基因在疾病的產(chǎn)生與發(fā)展中所起的作用。他們綜合使用生物信息及機器人系統(tǒng)來進行他們的高效能科研。這種做法使他們已辨認(rèn)了許多作爲(wèi)新藥目標(biāo)級分子診斷的蛋白質(zhì)。 

Founded in 1991, Myriad Genetics soon emerged as a world leader in the new field of molecular diagnostics. In addition to its molecular diagnostics business, Myriad has a strong drug development pipeline, Going forward, Myriad is uniquely positioned to develop and commercialize new molecular diagnostics and pharmaceuticals that prevent or mitigate the toll of mankind's deadliest diseases.

Pharmaceuticals
Myriad Pharmaceuticals is an organization with capabilities ranging from the identification of novel drug targets, discovery of lead molecules, development of drug candidates and finally, to designing and executing clinical programs. We believe our strategy is a model for success in the biopharmaceutical industry. We focus on disease areas for which there is a large, unmet medical need and we apply a novel approach to therapeutic development based on new technologies and new ways of looking at drug development problems.